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A b s t r A c t
 Conventional anticoagulant regimens are the mainstay of anticoagulant therapy 
that have been used for over 40 years in the treatment of thrombosis before newer 
agents became available. They include unfractionated heparin, low-molecular-weight 
heparins (LMWHs) and vitamin K antagonists (VKAs). Unfractionated heparin is 
a glucosaminoglycan which through binding to antithrombin accelerates thrombin 
inhibition. It is administered parenterally and has an immediate onset of action and 
a variable half-life related to the dose administered. Heparin causes prolongation of 
the activated partial thromboplastin time (aPTT) which is the assay used to moni-
tor its anticoagulant activity although lately anti-Xa activity assay has also been used 
for this purpose. The main adverse event of heparin treatment is hemorrhage. Other 
non-hemorrhagic serious adverse events are heparin-induced thrombocytopenia and 
osteoporosis. Heparin can be completely and rapidly reversed by the use of prota-
mine sulphate. LMWHs are fragments of unfractionated heparin and act via the same 
mechanism. LMWHs have replaced unfractionated heparin in most indications of 
use because their pharmacokinetic properties allow them to be administered once or 
twice daily without need for routine monitoring of their anticoagulant activity. How-
ever, in situations such as renal failure, obesity and pregnancy, where clearance of the 
drug is altered, monitoring is required and the anti-Xa activity is the recommended 
test. LMWHs have the same adverse events as unfractionated heparin but to a lesser 
extent owing to decreased binding to platelets and osteoblasts. Protamine only par-
tially reverses their anticoagulant effect. Vitamin K antagonists were the only orally 
administered anticoagulant agents until recently. They act through inhibition of the 
reduced form of vitamin K production which is necessary for anticoagulant factors II, 
VII, IX, X carboxylation and activation. Their many interactions with other drugs, 
foods and comorbid conditions render the stability of the anticoagulant response dif-
ficult and frequent monitoring is needed. The prothrombin time (PT) test is the most 
common test used to monitor VKA therapy and it is expressed as international nor-
malized ratio (INR), a standardized ratio of patient’s PT to normal PT. The lower and 
higher INR values beyond which the incidence of adverse events increases is defined 
as the therapeutic range. For most indications of VKAs the therapeutic range of INR 
must be 2.0-3.0. The most serious adverse event of VKAs is bleeding, with the rate in-
creasing as the INR rises >5. When reversal of anticoagulant effect is needed vitamin 
K is administered and in major bleeding vitamin K along with prothrombin complex 
concentrates (PCC) or fresh frozen plasma (FFP) is recommended.
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i N t r o d U c t i o N
The term conventional anticoagulant therapy is used to de-
scribe traditionally administered anticoagulants. These include 
unfractionated heparin and low-molecular-weight heparins 
(LMWH) and the orally administered vitamin K antagonists 
(VKAs). They have been the only anticoagulant drugs avail-
able for many decades and are still being widely used, despite 
the development of new anticoagulant agents, owing to their 
proved efficacy in many clinical settings.
U N F r A c t i o N A t e d  H e P A r i N
Unfractionated heparin is a glucosaminoglycan, consist-
ing of alternating disaccharide and pentasaccharide units, 
found in the secretory granules of mast cells. The most com-
mon disaccharide unit in heparin molecule is L-iduronate 
- D glucosamine.1 Heparin is an heterogenous molecule; the 
glucosaminoglycan chains vary in length, thus the molecular 
weight of heparin varies also, ranging from 3-30 kD, with 
a mean of 15 kD, which corresponds to approximately 45 
saccharide units.2 Commercial preparations of heparin are 
extracted from porcine intestinal mucosa or bovine lung which 
are reach in mast cells.1 
M e c H A N i s M  o F  A c t i o N
The heparin molecule does not have intrinsic anticoagulant 
activity, it exerts its action by binding to antithrombin, a poly-
peptide synthesized in the liver. Antithrombin (AT) circulates 
in plasma and inhibits the activated coagulation factors of 
intrinsic and common pathways (factors II, X, IX, XI, XII), 
whereas it has little activity on factor VII (Fig. 1). Heparin 
binds to antithrombin by a specific pentasaccharide sequence 
and induces a conformational change on its molecule, thereby 
converting antithrombin from a progressive, slow inhibitor 
to a very rapid inhibitor, enhancing its effect by 1000- fold.1-3 
Heparin then, dissociates from the complex and can be re-used. 
Thrombin and factor X are most sensitive to inhibition by 
heparin-antithrombin complex. For the inhibition of thrombin 
especially, heparin needs to be bound both to thrombin and 
antithrombin and this can be accomplished only by long-chain 
heparin molecules, with at least 18 saccharide units. With a 
mean molecular weight of 15000 D, almost all heparin mol-
ecules can serve this role. Consequently, by definition, heparin 
inhibits factor X and factor II to a similar extent (1:1).1-4 
Only one-third of heparin molecules possess the unique 
pentasacharide sequence and are responsible for the antico-
agulant activity of heparin. The remaining two-thirds have 
minimal anticoagulant effect at usual therapeutic doses, but 
at high concentrations (rarely used in clinical practice) they 
catalyze the antithrombin effect of a second plasma protein, 
heparin-cofactor II (HC II). At even higher concentrations 
heparin impairs factor Xa generation by an AT and HC II 
independent mechanism.2,5
Heparin exerts in vitro interaction with platelets, the 
high-molecular weight low-AT affinity molecules being more 
interactive. This interaction may contribute to heparin-induced 
bleeding with a mechanism independent of its anticoagulant 
effect.2 In addition to its anticoagulant effect, heparin attenu-
ates proliferation of smooth muscle cells; it inhibits osteoblast 
FigUre 1. Coagulation cascade and sites of action of conventional anticoagulants.
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formation and activates osteoclasts. These last two effects 
promote bone loss.2,5 
P H A r M A c o K i N e t i c s
Heparin is not absorbed from the gastrointestinal tract, and 
it is administered intravenously or subcutaneously. The onset 
of action is immediate when given intravenously, whereas it 
needs 1-2 hours when given subcutaneously. Subcutaneous 
route of administration decreases the bioavailability of heparin 
and larger doses (about 10% higher) are needed to overcome 
this reduction.1,2,4 Because heparin binds not only to antithrom-
bin but to other plasma proteins too, which neutralize its 
anticoagulant effect, its bioavailability varies among patients. 
Elevated levels of these proteins in patients with inflammatory 
and malignant conditions contribute to heparin resistance.2 
Heparin’s binding to endothelial cells and macrophages further 
complicates its pharmacokinetics. 
The elimination of heparin follows two different pathways: 
one readily saturable, by internalization and depolymerization 
into endothelial cells and macrophages and a slower one which 
is largely renal. The complex kinetics of heparin render the 
dose-anticoagulant response non-linear, the half-life of heparin 
rising disproportionally with increasing doses. At usual doses 
the half-life of heparin is approximately 45-90 min.2,6
d o s i N g
Randomized controlled trials have shown a relationship 
between heparin dose, efficacy and safety. Patients treated 
with lower starting doses had higher recurrence rates of 
thromboembolism, as also patients treated with standard 
dosing of heparin versus weight-based dosing. Those patients 
that achieved a therapeutic activated partial thromboplastin 
time (aPTT) during 24 hours had lower mortality rates.2 The 
recommended dose for intravenously given heparin is 80 units/
kg bolus infusion followed by 18 u/kg/h for venous thromboem-
bolism. Lower initial dose is recommended for cardiac patients, 
70 u/kg bolus infusion followed by 15 u/kg/h. A fixed dose of 
5000 u followed by 1000 u/h is an alternative dosing scheme. 
For subcutaneous use of heparin the recommended initial 
dose is 333 u/kg and 250 u/kg thereafter without monitoring.7
M o N i t o r i N g 
Given the relationship of heparin dose with efficacy and 
safety and the variability of anticoagulant response among 
different patients, it became a standard practice to monitor 
heparin response and to adjust the dose according to the 
anticoagulation tests. Heparin results in amplification of 
antithrombin-mediated inhibition of factors II, IX, X, XI and 
XII. Therefore heparin therapy at usual doses is associated 
with significant prolongation of the thrombin clotting time, 
aPTT and little, if any, prolongation of prothrombin time (PT); 
most PT reagents contain heparin neutralizer.8,9 Unfraction-
ated heparin at prophylactic doses does not prolong the aPTT.
For over 30 years the aPTT has been the assay used to 
monitor heparin therapy and the recommended therapeutic 
range was determined as 1.5-2.5 times the control value. Its use 
was based on a single observational study of 234 patients with 
venous thromboembolism (VTE)10 and its clinical relevance 
has not been confirmed by randomized trials.2 The measured 
response to aPTT varies between reagents and instruments 
used to measure the aPTT and the reagents and instruments 
used have changed over the last 25 years. The American Col-
lege of Chest Physicians (ACCP) and the College of American 
Pathologists (CAP) recommend that the therapeutic ranges 
of aPTT for a given institution must be determined by setting 
an aPTT range that correlates with an unfractionated heparin 
(UFH) activity of 0.3-0.7 units/ml by factor-Xa inhibition as-
say.2,11 For those heparin levels, modern aPTT reagents and 
coagulometers produce aPTT ratios that are 1.6-2.7 to 3.7-6.2 
times the control values. Therefore, the therapeutic aPTT 
range should be determined by each laboratory according to 
the responsiveness of the specific reagent being used. Like 
aPTT assays, anti-Xa assays also vary in their responsiveness 
to heparin; therefore standardization of aPTT ratios by refer-
ence to anti-Xa levels is also problematic.2
Thus, despite its standard use in monitoring unfractionated 
heparin, aPTT has certain drawbacks as a monitoring method: 
(1) There is need for aPTT standardization for each laboratory 
and each lot of testing reagent, because results are not equiva-
lent to the same result from another laboratory. Anti-Xa-relat-
ed aPTT method does not appear to enhance inter-laboratory 
agreement.2,12 (2) The aPTT is affected by many preanalytic, 
analytic and biologic variables. Examples of preanalytic factors 
are the underfilling of the tube or the extreme erythrocytosis 
of the patient. The aPTT can be prolonged in benign factor 
deficiencies such as factor XII or prekallikrein deficiencies or 
in the presence of lupus anticoagulant, which neither increases 
the risk of bleeding nor provides protection from thrombosis 
but may lead to heparin under-anticoagulation. On the other 
hand, antithrombin deficiency and increases in factors like 
VIII and fibrinogen, which are acute phase reactants, in certain 
inflammatory conditions, may blunt the expected prolonga-
tion of aPTT after heparin therapy (a phenomenon referred 
as ‘heparin resistance’), leading to over-anticoagulation and 
increased bleeding risk. In addition, aPTT is influenced by 
other conditions (liver dysfunction or vitamin K deficiency, or 
concomitant warfarin therapy) which may have a synergistic 
response to prolongation of aPTT beyond the one expected 
from the given heparin concentration.11-13 For all these reasons, 
aPTT has a low specificity in predicting the risk of bleeding.
Unfractionated heparin (UFH) can also be measured using 
an anti-Xa assay, which may be preferable to aPTT because 
it provides a direct measure of heparin activity.8 The test 
principle of anti-Xa assay is the inhibitory effect of heparin 
on factor Xa; reagent factor Xa in excess is added to patient 
plasma sample. Xa activity is neutralized in proportion to the 
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amount of heparin present in the plasma. The remaining factor 
Xa hydrolyzes a Xa-substrate releasing a colored signal that is 
measured photometrically. The amount of residual factor-Xa is 
inversely proportional to the amount of heparin in the sample. 
Results are expressed as units/ml of anti-Xa activity.11,13 Anti-Xa 
monitoring assay has its own limitations; first it is not available 
to all laboratories; it is poorly standardized (the inter-laboratory 
variation in the results is up to 30%);8 it is affected by elevated 
bilirubin and triglyceride levels; and it cannot reflect all antico-
agulant properties of heparin, nor other coagulation disorders 
that render the patient susceptible to adverse events.11-13 Most 
importantly, the overall impact of monitoring with anti-Xa 
assay in clinical outcomes remains unclear.11
Studies attempting to evaluate the relationship between 
aPTT and anti-Xa assay, although with small number of pa-
tients, show that there is an overall 50% discordance between 
the two assays11,12,14 and that monitoring patients with anti-Xa 
assay results in increased percentage of tests in therapeutic 
range, less dose modifications, fewer tests and probably less 
adverse events.11,13,15,16 Although the 2004 American Col-
lege of Chest Physicians evidence-based practice guidelines 
recommend aPTT for heparin monitoring, the 9th edition of 
Antithrombotic therapy and Thrombosis Prevention guidelines 
of 2012 do not make suggestions on heparin monitoring using 
the one over the other assay.2,5,13 More research is needed to 
identify the optimal approach in monitoring unfractionated 
heparin therapy.2,13
A d v e r s e  e v e N t s
The major adverse event of heparin therapy is hemor-
rhage in 1-5% of patients.1 The risk of bleeding increases 
with increasing dose of heparin and with co-administration of 
fibrinolytic agents or platelet glycoprotein IIb/IIIa inhibitors. 
The risk is also increased in advanced age, recent trauma or 
surgery.2 Other serious, non-hemorrhagic complications are 
heparin-induced thrombocytopenia and osteoporosis, resulting 
from heparin’s binding to platelets and osteoblasts, respec-
tively. The incidence of heparin-induced low bone density is 
around 30%,17,18 whereas symptomatic vertebral fracture may 
occur in up to 3 of every 100 people.17,19 The occurrence of 
osteoporosis appears to be related to the duration of treatment 
and the daily dosage.20 Other non-hemorrhagic side effects 
are very uncommon and include skin reactions, alopecia, 
hypersensitivity reactions and transient transaminasaemia.2
r e v e r s A l  o F  t H e  A N t i c o A g U l A N t  e F F e c t
Given the short half-time of heparin, management or 
prevention of bleeding can be achieved by stopping the infu-
sion of heparin. Heparin’s activity can be rapidly reversed 
by protamine sulphate, a protein extracted from fish sperm. 
Protamine binds to heparin and forms a stable inactive salt. 
One mg of protamine neutralizes 80-100 units of heparin. The 
dose of protamine is calculated according to the quantity of 
heparin administered the last two hours since the half-life of 
heparin when given intravenously is 60-90 min. Thus, if heparin 
is administered with a rate of 1000 u/h, 20 mg of protamine 
should be given to reverse heparin’s effect. For subcutaneously 
administered heparin, prolonged protamine administration 
should be considered, because protamine’s half-life is only 7 
min. The reversal effect of protamine can be monitored by the 
aPTT.1,2,21,22 Protamine at high doses may exert anticoagulant 
activity on its own, interacting with platelets, fibrinogen and 
other plasma proteins.1 Therefore it should be administered up 
to a maximum dose of 50 mg by a slow, intravenous infusion, 
slower than 5 mg/min, to avoid severe allergic reactions that 
include hypotension, bronchospasm and bradycardia,1,2,21 par-
ticularly in insulin-receiving diabetic patients having already 
been sensitized by protamine-containing insulin preparations 
(use of highly purified animal insulin or human recombinant 
insulin has significantly reduced this occurrence). 
l o w - M o l e c U l A r  w e i g H t  H e P A r i N s 
( l M w H )
Like unfractionated heparin, LMWH are glucosaminogly-
cans. They are produced from controlled chemical or enzy-
matic depolymerization of heparin, a procedure that results 
in chains of mean molecular weight around 5000 d, one-third 
of that of unfractionated heparin, which corresponds to 15 
saccharide units.2,3
M e c H A N i s M  o F  A c t i o N
The mechanism of anticoagulant activity is the same as that 
of heparin’s: binding to and activation of antithrombin via the 
unique pentasaccharide sequence. Only 15-25% of LMWH 
molecules contain this sequence. The main difference between 
heparin and LMWHs is the ratio of inhibition of factor Xa/ 
factor IIa. For thrombin (factor II) to be inhibited, simultane-
ously binding of heparin to antithrombin and thrombin must 
occur. Unfractionated heparin molecules are long enough to 
serve this role, but most of the low-molecular-weight-heparin 
chains are not. In contrast, all LMWH containing the pentasac-
charide sequence can inhibit factor Xa. Thus, while heparin 
has equivalent activity against factor Xa and factor IIa, low-
molecular-weight-heparins exert more anti-Xa activity and 
have anti-Xa/anti-II a ratios between 2:1 and 4:1.2,3 There 
has been much debate about the relative importance of anti-
Xa/anti-IIa activity in the anticoagulant effect of LMWHs. 
At present there is no evidence that differences in anti-Xa/ 
anti-IIa activity among LMWHs influence clinical outcomes, 
bleeding or thrombosis.2
P H A r M A c o K i N e t i c s
Compared to heparin, LMWHs exhibit less binding to 
plasma proteins, a fact that results in better bioavailability; 
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ing is often used to ensure constant anticoagulation, although 
there is no consensus on target concentration.23
Dosing in obese patients is not established. LMWHs clear-
ance correlates with lean body mass, therefore the addition of 
adipose weight in weight-based calculation of dose is not justi-
fied; dosing based on total body weight may result in excessive 
concentrations.23 However, in studies with enoxaparin but also 
dalteparin and tinzaparin, anti-Xa activity with total-weight-
based doses increased to appropriate levels in patients up to 
190 kg and there was no excess in the rate of major bleeding 
in obese patients over that observed in non-obese patients in 
total-weight-based adjusted doses.2 For thromboprophylaxis 
with fixed-dose of enoxaparine and nadroparine there is a 
strong negative correlation between anti-Xa levels and total 
body weight; thus, a weight-based prophylactic dose over a 
fixed dose is suggested for obese patients.26
Aged patients may be treated with LMWH at the same 
weight-adjusted doses as employed in younger adults. How-
ever, in elderly underweight patients (<45-50 kg), such dosing 
may result in an increased incidence of bleeding, and measures 
for use of lower dosing should be taken. 
Unfortunately there are no data on dosing modifications 
once the results of anti-Xa levels are known. Based on drug 
pharmacokinetics the dose-response is linear, and a rational 
approach is decreasing the dose if the clearance is in normal 
range or extending the frequency of administration when 
clearance is significantly reduced.23
A d v e r s e  e v e N t s
Low molecular weight heparins cause less bleeding than 
unfractionated heparin in laboratory animals3 and this is prob-
ably attributed to less binding with platelets and the neutral 
effect on vascular permeability compared to heparin. LMWHs 
can cause heparin-induced thrombocytopenia (HIT) and 
osteoporosis to a lesser extent than unfractionated heparin, 
because they bind less to platelets and osteoblasts, respec-
tively.2,27 Thus, the incidence of HIT is more than threefold 
lower with LMWHs. Osteoporosis has been studied mostly 
in pregnancy where it seems that with prophylactic doses the 
incidence of osteoporosis is low, comparable to that of non 
heparin-treated patients.28 
r e v e r s A l  o F  A N t i c o A g U l A N t  e F F e c t
Protamine reverses approximately 60% of the anticoagu-
lant effect of LMWHs.21 Protamine binds only to longer chain 
molecules of LMWHs which exert anti-II activity and fully 
reverses it. In contrast, anti-Xa activity which is mediated by 
short molecules is partially reversed by protamine.1,2,29 The 
clinical significance of incomplete neutralization of anti-Xa 
activity of LMWHs is unclear. Data on LMWHs reversal 
effects of protamine are relatively scarce. The largest study 
using protamine in patients on LMWH treatment showed 
that it prevented excessive bleeding in surgical patients and 
after subcutaneous injection the bioavailability is 90% ren-
dering the anticoagulant effect of LMWHs more predictable. 
Decreased binding to macrophages and endothelial cells of 
LMWHs results in longer half-life that is independent of dose. 
The elimination half-life after subcutaneous injection is 2-6 
hours. These superior pharmacokinetic properties allow for 
once or twice daily administration and eliminates the need for 
anticoagulation monitoring.1-3 Several studies have shown no 
benefit of monitoring and no association of anti-Xa levels with 
the rates of bleeding. Therefore monitoring is not generally 
recommended for the majority of patients.2
The clearance of LMWHs is mainly renal, and this limits 
their use in renal failure. Such cases require monitoring, as well 
as obese patients and pregnant women on treatment doses. 
Likewise, when anticoagulant effect is being questioned – oc-
currence of thrombosis or bleeding during therapy – monitor-
ing is advisable.2
For monitoring the anti-Xa level is recommended. As 
anti-Xa levels peak in 3-5 hours after dosing the peak concen-
tration following is approximately 4 hours after dosing. For 
venous thromboembolism a conservative peak anti-Xa level 
with twice daily enoxaparin is 0.6-1.0 u/ml. The peak anti-Xa 
level is different for each LMWH preparation; for a certain 
preparation the once or twice daily doses differentiate the 
peak. Thus, the target anti-Xa level for once daily enoxaparin 
is above 1.0 u/ml.2,23
d o s i N g  i N  s P e c i A l  s i t U A t i o N s
Appropriate dose in patients with renal insufficiency, 
overweight patients and pregnant women is uncertain be-
cause such patients are excluded from large, randomized 
trials. Monitoring with anti-Xa assay provides some guid-
ance to dosing.
Results from pharmacokinetic studies with therapeutic 
doses of enoxaparin and dalteparin show a clear relationship 
between anti-Xa levels and renal clearance, the anti-Xa levels 
rising when clearance declines to <30 ml/min. The same is 
observed, though less frequently, after prophylactic doses of 
enoxaparin. Decreased renal clearance was shown to increase 
the risk of bleeding in patients with creatinine clearance (CrCl) 
<30 ml/min treated with therapeutic enoxaparin dose. Pro-
phylactic doses did not increase the risk of bleeding in trials 
even at CrCl <30 ml/min. Use of unfractionated heparin in 
patients with renal insufficiency is a treatment option in or-
der to avoid the bioaccumulation that occurs with LMWHs. 
If LMWHs are administered, the dose should be reduced to 
about 50% for enoxaparin. Data are lacking for other LMWH 
preparations.2,23,24
Pregnancy alters renal function and fluids distribution thus 
affecting the clearance and distribution of the drugs. Data 
suggest that there is a higher LMWH turnover in pregnancy 
and thus higher doses are required for both treatment and 
prophylaxis.23,25 In high-risk patients, trough anti-Xa monitor-
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effectively managed active bleeding in 8 out of 12 bleeding 
patients. Anti-Xa levels did not correlate with the likelihood 
of persistent bleeding. Recombinant factor VII for the reversal 
of LMWHs has not been evaluated in clinical trials, but in a 
few case reports.2,21,29
If reversal of LMWHs activity is needed within the last 8 
hours of administration, protamine sulphate is given in a dose 
of 1 mg for every 100 anti-Xa units of LMWH up to a maximum 
dose of 50 mg. A second dose of 0.5 mg of protamine per 100 
anti-Xa units is considered if bleeding has not been controlled. 
Smaller doses are administered if LMWH was given over than 
8 hours prior to the time of correction.2,21
c l i N i c A l  i N d i c A t i o N s  
F o r  H e P A r i N  U s e
Both unfractionated and LMWHs are currently being used 
for prophylaxis and treatment of venous thromboembolism 
and pulmonary embolism in medical and surgical patients - 
especially orthopedic patients in hip and knee replacement 
operations – and also in pregnancy and peripartum. They are 
also administered in acute coronary syndromes and myocardial 
infarction30,31 (Table 1). For most of these indications, LMWHs 
have replaced unfractionated heparin due to their proven 
efficacy and convenience of use that includes administration 
once or twice daily and no need for monitoring in the majority 
of patients. They are also associated with fewer adverse events 
(major hemorrhage, osteoporosis, HIT) compared to unfrac-
tionated heparin. A limitation of LMWHs use is renal failure 
(CrCl <30 m/min), as they are predominately cleared by the 
kidneys and their biologic half-life may be prolonged in renal 
impairment; in such patients dose reduction or an alternative 
anticoagulant should be considered. Unfractionated heparin 
remains the drug of choice in cardiopulmonary bypass opera-
tions and hemodialysis.32,33
LMWH is the preferred agent for venous thromboembo-
lism (VTE) prevention after a major orthopedic operation 
(total knee or hip arthroplasty or hip fracture surgery) and it 
should be administered for at least 10-14 days after the op-
eration.32 Extending thromboprophylaxis up to 35 days after 
surgery should be considered in these patients. For pregnant 
patients, LMWHs are the recommended agents for prophylaxis 
and treatment of VTE.32
LMWH is the drug of choice for both initial and long-term 
treatment of cancer-related venous thromboembolism.32,34,35 
Cancer patients have an increased risk of VTE recurrence and 
bleeding complications while receiving anticoagulant therapy. 
Long term anticoagulation with LMWHs is associated with 
a significant reduction of thrombosis recurrence without a 
statistical significant increase in bleeding risk compared with 
VKAs.35,36 Treatment duration of at least 6 months or as long 
as the malignancy is active is recommended.34,37
H e P A r i N  i N d U c e d 
t H r o M b o c y t o P e N i A
Heparin induced thrombocytopenia (HIT) is a life-
threatening, procoagulant disorder occurring in 0.2-5% of 
patients recently exposed to unfractionated or, less commonly, 
LMWH.38,39 Patients typically present with low platelet count, 
and thromboembolic manifestations affecting 20-50% of 
patients.38,40 The syndrome is associated with mortality rates 
of 5-10% usually as the result of thrombotic complications.41
The syndrome is caused by IgG antibodies against heparin-
platelet factor 4 (PF4) complex38,39,41 which binds to FcγIIa 
receptor on platelet surface – but also to monocytes and 
endothelial cells – activating them. Platelet’s activation and 
aggregation results in thrombocytopenia and releases proco-
agulant microparticles that further activate the coagulation 
cascade with thrombin production.41 Heparin-PF4 antibodies 
are present in all patients who develop HIT but they are also 
present in many patients exposed to heparin without clinical 
manifestations.38,41 Why some antibodies are pathogenic and 
others not is not clear, but this may relate to the titer of the 
antibody or the size of heparin-PF4 complex.41
tAble 1. Current indications for the use of heparin.
Prevention of venous thromboembolism in
• Medical patients at high risk
• Surgical patients at high risk
• surgical patients with cancer




Pregnancy (for both prevention and treatment of vte/Pe)
Acute coronary syndromes
• with or without STEMI
• primary PCI or not 
Acute limb ischemia
Hemodialysis 
Coronary artery bypass grafting surgery
Indications shown with bold letters are those for which unfractionated 
heparin has been replaced by LMWHs as first line treatment according 
to the latest ACCP recommendations.
ACCP: American College of Chest Physicians; HFS: hip fracture 
surgery; LMWH: low-molecular weight heparin(s); PCI: percutaneous 
coronary intervention; PE: pulmonary embolism; STEMI: ST elevation 
myocardial infarction; THA: total hip arthroplasty; TKA: total knee 
arthroplasty; VTE: venous thromboembolism.
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Risk factors for HIT development are drug-related and 
patient-related. Heparin related risk factors are type of heparin 
and duration of treatment. LMWH is associated with a 5-10 
fold lower risk of HIT than unfractionated heparin,39 and the 
overall incidence is 0.2-1% compared to 1-5% with UFH. The 
risk is higher as the duration of therapy rises to more than 5 
days39,41,42 and with full dose anticoagulation.42 Older patients 
and women are at increased risk. Surgical patients have a 
higher risk than medical patients, orthopedic patients being 
at particular high risk.
Thrombocytopenia occurs usually after 4-15 days of 
heparin administration and may be absolute (<150x109/ml) 
or relative, with a 50% reduction from the count on the day 
of commencement of heparin. Platelet count rarely fall below 
20x109/ml, are rarely associated with bleeding and they rise 
again within 4-14 days after heparin cessation.38,39 In patients 
previously exposed to heparin (during the last 30 days) who 
also have heparin-PF4 antibodies, platelet count drops rapidly, 
within hours of heparin exposure.38,39,41
Thrombotic complications can occur simultaneously 
or may arise after platelet count drop.38,41 In a series of 
patients, thrombosis appeared before any apparent fall in 
the platelet count.38 Thrombosis can complicate the clinical 
course of patients with thrombocytopenia even after heparin 
discontinuation if an alternative antithrombotic agent is not 
administered.27,39 The rate of venous to arterial thrombosis is 
4:1. Patients typically present with deep venous thrombosis or 
pulmonary embolism but thrombosis in unusual sites can occur, 
such as splanchnic vein or cerebral venous sinuses.38,41 Arterial 
thromboembolism, most commonly affecting the extremities 
is also common particularly after cardiac surgery and can pro-
gress to limb necrosis necessitating amputation.39,41 Myocardial 
infarction and stroke are among less often manifestations.40
Establishing the diagnosis of HIT in patients with compli-
cate clinical courses is challenging, thought suspicion of the 
diagnosis on clinical grounds is essential for clinical outcome. 
HIT should be suspected in any patient exposed to heparin 
who presents with thrombocytopenia and thrombosis. Other 
causes of thrombocytopenia must be excluded to prevent un-
necessary and potential harmful treatment. Several clinical 
scoring systems have been developed in order to help clini-
cians establish the probability of HIT, including the 4T score43 
and the Hit Expert Probability (HEP) score.41 These scoring 
systems have high negative predictive value but low positive 
predictive value 41,44 though, and may be useful in combination 
with laboratory results in establishing a diagnosis.
Two general serologic assays for HIT are used: quantitative 
enzyme immunoassays that detect antibodies against heparin-
PF4 complex and functional assays that measure platelet acti-
vation induced by these antibodies. 38-41 Enzyme immunoassays 
are readily available and have a high sensitivity, almost 100%, 
but low specificity. Functional assays such as serotonin-release 
assay or heparin-induced platelet aggregation test are both 
sensitive and specific but are not widely available and their 
technical requirements restrict their use in reference labora-
tories.39,41 Serologic testing for anti-heparin-PF4 antibodies is 
recommended in patients with a high or intermediate probabil-
ity score in which strongly positive results make the diagnosis 
more probable and negative results precludes it.39,41 In such 
patients functional assays further affirm the diagnosis though 
they are not considered necessary.41 In patients with intermedi-
ate probability and positive serologic results a functional assay 
may help to establish the diagnosis.38,41
The goals of management of HIT is to reduce thrombotic 
risk by reducing platelet activation and thrombin production. 
Heparin administration must be discontinued immediately 
in high or intermediate clinical suspicion of HIT including 
heparin used to maintain patency of intravenous lines, and 
alternative anticoagulant therapy should be offered. LMWHs 
should not be used as an alternative treatment since they can 
form complexes with PF4 that are capable of binding HIT 
antibodies. Consequently in patients with HIT there is cross-
reactivity of LMWHs and they should not be used.2,27 The most 
appropriate anticoagulant for heparin induced thrombocyto-
penia remains uncertain. Studies evaluating the anticoagulant 
used for HIT suffer important methodologic limitations, 
including the use of historical controls, small sample sizes and 
inconsistencies in diagnosis.41 The ACCP makes a weak recom-
mendation for the use of argatroban or lepirudin (both direct 
inhibitors of thrombin) or danaparoid (antithrombin-mediated 
Xa inhibitor) over other non-heparin anticoagulants.32 The 
British Committee for Standards in Haematology (BCSH) 
recommends danaparoid and alternatively argatroban for 
patients with HIT.27 Lepirudin is no more available in both 
United States and Europe and danaparoid was withdrawn from 
the United States market in 2002. Fondaparinux, an indirect 
inhibitor or factor Xa, has been increasingly used and is an 
acceptable alternate although it has not been licensed for this 
indication.27,32,41 Because HIT carries a high risk of subsequent 
thrombosis, long-term anticoagulation therapy is needed. Vi-
tamin K antagonists should be administered but only after the 
platelet count has returned to normal levels since they have the 
potential of aggravating thrombosis through rapid reduction 
of protein C. For isolated heparin induced thrombocytopenia, 
anticoagulation continues for six weeks. When thrombosis has 
occurred duration is extended up to 3-6 months.27,32,41
v i t A M i N  K  A N t A g o N i s t s
Vitamin K antagonists (VKAs) are anticoagulants that 
have been successfully used for many decades in a variety 
of clinical settings. Numerous anticoagulants have been syn-
thesized as derivatives of 4-hydroxycoumarin or the related 
compound indandione. Compounds that are widely being 
used currently are 4-hydroxycoumarin derivatives, mainly 
CONVENTIONAL ANTICOAGULANTS
217
warfarin (Coumadin, Panwarfin), but also acenocoumarol 
(Sintrom) and phenprocoumon. Anisindione and phenindione 
(indandione derivatives) are not in use because of serious 
adverse effects.1
i N d i c A t i o N s  F o r  U s e
Vitamin K antagonists are currently used for primary and 
secondary prophylaxis from venous and arterial thromboembo-
lism. In particular, they are administered for thromboprophy-
laxis after orthopedic procedures, in patients with thrombo-
philia and for the prevention of arterial thromboembolism 
in patients with atrial fibrillation, prosthetic heart valves and 
rheumatic mitral valve disease. They have been the treatment 
of choice for long-term therapy of venous thromboembolism 
and pulmonary embolism.32 
M e c H A N i s M  o F  A c t i o N
VKAs interfere with vitamin K oxidation-reduction cycle. 
Coagulation factors II, VII, IX, X (Fig. 1) and anticoagulant 
proteins C and S are synthesized in the liver and they are 
not effective unless they undergo a carboxylation to form 
calcium binding sites. The carboxylation procedure requires 
the reduced form of vitamin K. Oral anticoagulants exert 
their anticoagulant effect by targeting Vitamin K Oxidase 
Reductase (VKOR) an enzyme responsible for the reduction 
of vitamin K in vitamin K cycle.1,45 Thus, the coagulation factors 
are produced in the liver but they have reduced anticoagulant 
activity by 10-40%.1 
P H A r M A c o K i N e t i c s
Warfarin is water soluble and it is rapidly absorbed from 
the gastrointestinal system. Food can decrease the rate of ab-
sorption. It is usually detectable in the plasma after one hour 
of its administration and reaches maximum concentration 
in about 2 hours.1,45 It is almost completely (98%) bound to 
plasma proteins, mainly albumin, and it is rapidly distributed 
in plasma. Fetal plasma concentrations are almost equal to 
maternal concentrations, therefore it is contraindicated in 
pregnancy.1 VKAs are metabolized in the liver. Most of them 
are racemic mixtures of R and S enantiomers. For warfarin 
the S-enantiomer and for acenocoumarol the R-enantiomer 
are the most potent isomers and they are both metabolized by 
CYP2C9 enzyme of P450 cytochrome. Warfarin has a half-life 
of 36-42 hours; acenocoumarol 10-24 hours.1,45
Pharmacokinetics and pharmacodynamics of VKAs can be 
modified by genetic polymorphisms in CYP2C9 and VKORC1 
genes. Most common polymorphisms of CYP2C9 gene is 
CYP2C9*2 CYP2C9*3. About 20% of Caucasians and less 
than 5% of African-Americans and Asians carry these poly-
morphisms.1 People who carry them tend to have increased 
levels of S-warfarin because of impaired ability to metabolize 
it. These individuals need lower doses of warfarin; heterozy-
gotes may need 20-30% and homozygotes up to 50-70% dose 
reduction.1,45 Some have shown that genetic polymorphisms are 
also related to high rates of bleeding.45 VKORC1 variants are 
more common than CYP2C9 ones. The prevalence is higher 
in Asian-Americans. People with polymorphisms have altered 
sensitivity to inhibition of VKORC1 by warfarin and probably 
need from 20% to 50% dose reduction (for heterozygotes and 
homozygotes respectively).1,7,45
Studies that have attempted to compare time in therapeu-
tic range (TTR) in patients treated with genetic-based and 
clinical-based dose strategies gave inconsistent results.7,45 The 
pharmacogenetic-based dosing scheme was better in predicting 
TTR in people requiring very high or very low weekly doses 
but it did not affect dosing calculation in intermediate doses. 
As yet, it is not proven that genetic testing is related to bet-
ter clinical outcomes. The 9th edition of ACCP guidelines do 
not recommend pharmacogenetic testing for guiding dose.7,45 
Randomized controlled trials gave inconsistent results of phar-
macogenetic based dose over clinical-based dose in TTR.46-48 
None of these trials was designated to address the influence 
of pharmacogenetic testing in the rate of bleeding/thrombosis. 
A meta-analysis of studies published recently have shown a 
50% reduction of serious bleeding events by approximately 
50% with pharmacogenetic-guided dosing.49 The Genetics 
InFormatics Trial (GIFT) may give convincing evidence. This 
is an ongoing randomized controlled trial, assessing the safety 
and effectiveness of pharmacogenetic guided warfarin dosing 
for the reduction of deep vein thrombosis compared with clini-
cal algorithm dosing following total hip or knee repair. The 
primary end-point is a composite of venous thromboembolism, 
hemorrhage, INR >4 or death.50
d r U g  A N d  F o o d  i N t e r A c t i o N s
VKAs are very sensitive to drug-drug interactions, thus 
making the anticoagulation management troublesome in 
routine practice. The mechanisms by which drugs interact with 
VKAs include: reduction of their absorption in the gastroin-
testinal tract (cholestyramine), increased clearance by liver 
enzyme induction (carbamazepine, rifampicin, barbiturates), 
decreased clearance by CYP2C9 inhibition (amiodarone, an-
tifungals, clopidogrel, metronidazole), inhibition of vitamin K 
cycle (cephalosporins) or elimination of bacteria flora (sulfona-
mides, broad spectrum antibiotics), enhancement of clearance 
of vitamin K dependent coagulation factors (thyroxine) or 
interference with other hemostatic parameters (antiplatelets, 
non-steroidal anti-inflammatory drugs - NSAIDS).1,7,45 The 
most effective way to avoid drug interaction is to avoid co-
administration. If that is not possible a more frequent moni-
toring of the anticoagulant effect may help avoiding adverse 
events.45 Hemorrhagic episodes have been shown to increase 
when VKAs are administered along with antiplatelet agents, 
antibiotics and NSAIDS, therefore according to 9th ACCP 
recommendation the concomitant use of these drugs should 
be avoided whenever possible.7
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Patients taking VKAs are sensitive to fluctuations of 
dietary vitamin K which is derived from plants. An increased 
oral intake of vitamin K that is sufficient to reduce the antico-
agulant response to warfarin can occur in patients consuming 
green vegetables or vitamin-K containing supplements, or 
those on weight reduction diets. More sensitive are vitamin-K 
deficient patients. In general, a consistent intake of vitamin K 
is recommended, and no specific restrictions or additions are 
recommended in patients with stable anticoagulant control.7,45
A N t i t H r o M b o t i c  e F F e c t
By reducing anticoagulant factors’ activity, VKAs induce 
prolongation of both PT and aPTT. Vitamin K antagonists 
have no effect on already carboxylated factors in the circu-
lation, which sustain their anticoagulant activity for some 
time related to their half-lives. Half-lives of these factors (in 
hours) are approximately as following: factor VII: 6; factor 
IX: 24; factor X: 36; factor II: 50; protein C: 8; protein S: 30 
hours. Therefore, although the prolongation of PT occurs 
relatively soon after administration of VKAs, reflecting 
reduction of coagulation factors with short half-life (such 
as factor VII), the full antithrombotic effect which is mainly 
attributed to reduction of factor II1,45 is not established until 
several days have passed. This is the basis for overlapping the 
administration of VKAs with parenteral agents when rapid 
anticoagulation is needed. According to latest recommenda-
tion, VKAs are administered one or two days after initiation 
of LMWH or UFH.7
M o N i t o r i N g
The prothrombin time (PT) is the test used to monitor 
the anticoagulant effect of VKAs. PT is performed by adding 
thromboplastin and calcium to citrated plasma. The ability of 
each thromboplastin to prolong the PT for a given reduction 
of coagulation factors varies among different reagents, thus 
when PT is expressed in seconds or as a ratio of patient / mean 
normal, PT is not standardized. Comparison of the thrombo-
plastin used in a laboratory to the International Reference 
Thromboplastin used by the World Health Organization gives 
the International Sensitivity Index (ISI) of the reagent; the 
more responsive the reagent the lower the ISI value which 
ideally is equal to 1. A model adopted in 1982 for standardizing 
PT results is converting PT to INR (International Normalized 
Ratio) according to the following equation: INR = (patient’s 
PT/mean normal PT)ISI.1,45
Although introduction of the INR system has improved 
the laboratory monitoring of patients on oral anticoagulant 
therapy, the INR will not be identical with different thrombo-
plastins. ISI values of each thromboplastin reagent, as well as 
mean normal PT determined with the reagent, should be pro-
vided by the manufacturer of thromboplastin reagent. Several 
studies have shown that the ISI and the mean normal PT are 
not a function of thromboplastin alone but also of the method 
and coagulometer used. Thus, the mean normal PT and the 
instrument-specific ISI for each reagent should be determined 
locally. In general, the College of American Pathologists has 
recommended that laboratories should use thromboplastin 
reagents that are at least moderately responsive (ISI <1.7) 
and reagent/instrument combinations for which the ISI has 
been established and validated.45
The INR is based on ISI values derived from the plasma 
of patients who had received stable anticoagulant doses for 
at least 6 weeks; thus, the validity of INR in the early course 
of warfarin therapy as well as in patients with other condition 
of coagulation impairment (i.e. liver disease) has not been 
adequately evaluated. Another issue is that INR values can 
be affected by collection tube underfilling because of higher 
citrate concentrations.45 
Initial testing is usually performed after 2-3 doses in 
outpatients. Frequency of monitoring depends on patient’s 
compliance, comorbid conditions, concomitant use of drugs 
interacting with VKAs or changes in diet and whether the pa-
tients have demonstrated stable INR. If two consecutive weekly 
INR values are within range, the interval between draws could 
be extended to monthly.51 The INR is considered particular 
stable if the results are consistent for at least 3 months without 
dose adjustments. Retrospective and observational studies 
have generally shown that increasing monitoring intervals 
may either increase or decrease the time in therapeutic INR 
range but three randomized studies demonstrated than in 
stable patients, the monitoring frequency can be extended to 
every 4 weeks or even more (12 weeks in particularly stable 
patients) without the rates of bleeding or thrombosis being 
increased.7,45 Factors that have been shown to influence long-
term INR stability are age >70 years, comorbid conditions, 
physical activity, vitamin K deficiency but most importantly 
patient’s adherence to treatment. 
Numerous studies have shown that patient self-testing 
(self-testing and informing the treating physician) or self-
monitoring (self-testing and self-deciding dose management) 
using one of the approved point-of-care INR measurement 
devices are related to greater INR stability and decrease of 
adverse events.7,45,52,53 However, these practices may not be 
suitable to most patients and their implementation requires 
high patient motivation and training.7,45,52 
Therapeutic range is the range of INR levels beyond which 
the rate of adverse events increases. Time in therapeutic range 
(TTR) serves as a function of anticoagulant treatment quality 
and has been consistently related to fewer adverse events in tri-
als in diverse clinical settings.45 When moderate intensity INR 
(2.0-3.0) was compared to high-intensity oral anticoagulation, 
the former proved to be related to fewer bleeding rates without 
reducing efficacy. In a systematic review of 19 studies, with 
more than 80,000 patients reporting clinical outcomes in three 
different INR ranges, the lower rate for composite outcomes of 
major bleeding and thromboembolism was seen in INR range 
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2.0-3.0.7 Low-intensity (INR <2.0) anticoagulation in patients 
with venous thromboembolism or atrial fibrillation was inferior 
to moderate intensity treatment in terms of efficacy without 
protecting patients from major bleeding. Therefore the optimal 
INR range recommended by ACCP and BCSH for patients 
on VKA treatment for most clinical indications is 2.0-3.0, in-
cluding patients with thrombophilia. A possible exception are 
patients with mechanical mitral valve for whom therapeutic 
INR range is recommended to be 2.5-3.5.7,52,54
A d v e r s e  e v e N t s
Bleeding is the most common adverse event of VKAs, oc-
curring with an incidence of 1.5-3.0% annually.7,29 The most 
important risk factor for bleeding is treatment intensity; risk 
is substantially increased when INR rises >4.5.1,7,45 Several 
patient characteristics are associated with higher rates of 
bleeding during anticoagulation, with history of bleeding being 
the most consistent predictive factor,45 necessitating searching 
for a potential anatomic source of hemorrhage especially in 
the gastrointestinal tract. Other patient-related factors are 
advanced age and comorbid conditions.
Apart from hemorrhage, thrombotic complications such 
as skin necrosis and limb gangrene are important side effects 
of VKAs but uncommon. They occur on 3-8th day of therapy 
and they are probably attributed to rapidly decline levels of 
protein C in deficient individuals, however this complication 
occurs also in non deficient patients. Management is difficult, 
requiring discontinuation of VKA and substitution by a par-
enteral anticoagulant agent. Re-initiation of VKA treatment 
for long-term anticoagulation is attempted under heparin 
coverage with small, gradually increased doses.45
A very rare adverse event is the purple toe syndrome, de-
veloping 3 to 8 weeks after initiation of therapy with sudden 
appearance of painful, bilateral, purple lesions of the toes that 
blanch with pressure.45
r e v e r s A l  o F  A N t i c o A g U l A N t  e F F e c t
Vitamin K can reverse the anticoagulant effect of VKAs, 
promoting the reduction of vitamin K epoxide via a reductase 
enzyme insensitive to VKAs. Orally administered vitamin K 
starts to correct INR in about 12-16 hours, whereas intrave-
nously administered has a more rapid effect, the reduction 
starts at 2 hours and the INR value returns to normal in ap-
proximately 24 hours.45 In urgent situations like major bleeding 
or an invasive procedure, where rapid reversal of anticoagula-
tion is required, vitamin K serves as a maintenance treatment, 
with infusion of coagulation factors being the cornerstone 
of management. Traditionally, fresh frozen plasma (FFP) is 
widely being used but it has certain limitations: thawing time 
makes it not readily available, it partially corrects the INR, it 
can cause volume overload and carries all the adverse events 
of a transfusion, including infection transmission and transfu-
sion related acute lung injury (TRALI) risk.22,45 Prothrombin 
complex concentrate (PCC) is recommended over FFP7,21,22 for 
anticoagulation reversal because it is administered in a small 
volume of fluid, it fully corrects the INR in less than 30 min21 
without the risk of infection transmission although it has not 
been compared with FFP in adequately powered randomized 
trials.7 PCC may be classified as three-factor products (with 
adequate levels of factors II, IX, X and low levels of factor 
VII) and four-factor products containing adequate levels of 
all vitamin-K dependent factors plus protein C and S.21,22,45 
The optimal dose is not yet established; a large dose scale 
has been used in clinical trials ranging from 8-50 u/kg with 
relatively good clinical and INR outcomes with the use of any 
treatment protocol.55 Recombinant factor VII can be used in life 
threatening bleeding but suffers lack of evidence.7
According to the latest ACCP and BCSH guidelines, 
emerging reversal of anticoagulation requires administration 
of PCC at a dose of 25-50 u/kg and intravenous vitamin K at 
5-10 mg. If PCC is not available, FFP should be given.7,21,29 For 
non-major bleeding only vitamin K intravenously administered 
at a dose of 1-3 mg is recommended. Patients with INR >5 
but <10 who are not bleeding should have one or two doses of 
VKA withheld without administration of vitamin K. For INR 
>10 in asymptomatic patients holding one or two doses along 
with oral vitamin K 1-5 mg is recommended.7,21
P e r i P r o c e d U r A l  A N t i c o A g U l A t i o N
The question of whether the anticoagulant therapy should 
be discontinued before a planned invasive procedure involves 
balancing the risk of postoperative bleeding with continued 
treatment against the thrombotic risk with discontinuation 
of therapy and bridging anticoagulation.56 Bridging antico-
agulation refers to the practice of giving a short-acting blood 
anticoagulant, usually subcutaneous heparin, for 10-12 days 
around the operation, when VKAs are interrupted, in order 
to prevent thromboembolic events but it carries the risk of 
increased postoperative bleeding.
According to latest guidelines,57 patients who are under-
going a minor operation with low risk of bleeding can safely 
continue the anticoagulant therapy especially if they are at 
high-thromboembolic risk. Conversely, patients planned to 
have a high-bleeding risk operation can discontinue the 
antithrombotic therapy if their thrombotic risk is low. For 
patients at intermediate or high risk of thrombosis undergoing 
high-bleeding risk procedures the decision is challenging. As-
sessment of thrombotic risk, type of procedure and procedure-
related bleeding, duration of action of anticoagulants and 
time of cessation and reinstitution of antithrombotic agents 
should all be taken into account to help the decision-making 
process. An important consideration in assessing procedure-
related bleeding risk is that minor procedures which are not 
typically associated with bleeding may be complicated by 
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bleeding in the context of peri-procedural administration of 
antithrombotic agents.57
When anticoagulant agents are discontinued in high risk 
patients, this must be done 5 days before the procedure and 
when the INR falls below therapeutic range, bridging therapy 
–if needed, in high risk patients- is started. Bridging therapy 
consists of subcutaneous low-molecular weight heparin or in-
travenous unfractionated heparin usually at therapeutic doses. 
In patients with deterioration of renal function, unfractionated 
heparin is given. If UFH is administered it should be stopped 
4-6 hours before the operation. If LMWH is administered the 
last dose is given 24 hours before the procedure. If hemostasis 
is achieved, bridging therapy is reinitiated 48-72 hours after 
the procedure,52,56,57 whereas VKA can be reinstituted 12-24 
hours postoperatively.
Although bridging anticoagulation has been considered the 
standard of care for high-risk patients, it has been evaluated in 
only a few randomized trials and its usefulness remains contro-
versial.56 Because of the paucity of high-quality evidence, avail-
able guidelines are giving weak and inconsistent recommenda-
tions for the implementation of bridging anticoagulation.57,58 
A recent meta-analysis showed that bridging anticoagulation 
is associated with more bleeding episodes with no respective 
reduction of thrombotic risk.59 Moreover there are also other 
meta-analyses in patients undergoing pacemaker or implant-
able cardioverter defibrillator implantation surgery showing 
that maintenance of anticoagulant treatment is associated 
with significant lower bleeding postoperatively compared to 
heparin-based bridging anticoagulation with no difference in 
risk of thrombosis.60,61 These results have been confirmed by a 
randomized trial which showed that continuing VKA therapy 
during implantation of cardioverter defibrillator is associated 
with significant reduction in the incidence of device-pocket 
hematoma compared to bridging anticoagulation with hepa-
rin.62 A recent randomized double-blinded trial (BRIDGE) 
showed that in patients with atrial fibrillation who discontinued 
the VKA regimen in order to undergo an invasive procedure, 
no-bridging was not inferior to bridging anticoagulation with 
LMWH for the prevention of arterial thromboembolism 
and decreased the risk of major bleeding.63 Thus, while the 
antithrombotic efficacy of bridging anticoagulation with LM-
WHs has not been demonstrated, increasing bleeding risk is 
observed in different types of surgery.64
P r e g N A N c y  A N d  A N t i c o A g U l A N t s
During pregnancy anticoagulants are used for the fol-
lowing indications: (1) prevention and treatment of VTE, 
(2) prevention and treatment of systemic embolism in women 
with mechanical valves, (3) prevention of VTE in patients with 
thrombophilia, and (4) prevention of recurrent pregnancy loss 
in women with antophospholipid syndrome in combination 
with aspirin.65 An important issue of anticoagulation in preg-
nancy is both mother’s and fetus’s safety. LMWHs and UFH 
are safe for the fetus as they do not cross the placenta or enter 
breast milk. In contrast, VKAs are contraindicated because 
they cross the placenta and are associated with embryopathy, 
central nervous system abnormalities, pregnancy loss and fetal 
anticoagulation with possible bleeding. Embryopathy typically 
occurs after in utero exposure to VKAs during the first trimes-
ter of pregnancy.65 They are considered safe during lactation. 
Maternal safety is mandatory since pregnancy is virtually the 
only indication where heparins are given over a prolonged 
period. The most important maternal safety issue for any an-
ticoagulant is the risk of bleeding. LMWH is associated with 
less bleeding and the risk of HIT and osteoporosis appears 
much lower compared to UFH.25,65,66 Thus, LMWH is the drug 
of choice for anticoagulation during pregnancy because is as 
effective as UFH for prevention and treatment and has better 
bioavailability, longer plasma half-life, more predictable dose 
response and improved safety profile compared to UFH.65,67,68 
It should be noted, however, that the evidence guiding 
the use of prevention and treatment of thromboembolism in 
pregnancy is mostly derived from non-randomized, observa-
tional studies and from extrapolating the results of randomized 
trials involving non-pregnant women. Thus, there are several 
issues concerning the use of therapeutic and preventive doses 
of LMWH that remain controversial. These include the most 
appropriate regimen, the dose-adjustment according to the 
increasing body weight, the dosing schedule (once versus 
twice daily), the possibility of lowering the dose after initial 
treatment, the need for anti-Xa activity monitoring as well as 
the optimal duration of treatment.65,66,69 Many clinicians use 
an once daily regimen to simplify administration and enhance 
compliance. Routine monitoring of therapeutic anti-Xa 
levels cannot be recommended and it is performed only in 
extremely over-weight women or those with renal impairment, 
while other clinicians prefer to periodically monitor anti-Xa 
to maintain therapeutic LMWH levels. Treatment duration 
should be no less than 3 months and should cover at least the 
first six weeks after delivery. For postpartum prophylaxis and 
treatment either LMWH or a VKA can be used.65,67,68
Heparin treatment should be discontinued 24 hours before 
planned delivery to minimize the risk of bleeding and allow 
the option for neuraxial anesthesia. Neuraxial anesthesia is 
avoided if less than 24 hours of heparin injection have elapsed 
because of the risk of epidural hematoma.65
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